Takeda Receives Positive CHMP Opinion Recommending Approval

ZURICH, Sept. 22, 2023 /PRNewswire/ -- Takeda (TSE:4502) (NYSE:TAK) today announced the European Medicines...

Related Keywords

Zurich , Züsz , Switzerland , United States , United Kingdom , Japan , British , Prnewswire Takeda , Didier Relin , Takeda Pharmaceutical Company , Takeda Pharmaceutical Company Limited , European Academy Of Allergy , European Medicines Agency , European Commission , Clinical Immunology Hybrid Congress , Committee For Medicinal Products Human Use , Head Of International Regulatory At Takeda , Lanadelumab Will , First Long Term Prophylactic Treatment , Patients Under , Opinion Based , Pivotal Study , Safety Profile , Pivotal Adult , Adolescent Study , Genetic Disorder Estimated , Affect About , Condition Results , Recurring Attacks , Various Parts , Medicinal Products , Human Use , Hereditary Angioedema , International Regulatory , Open Label Phase , Evaluate Safety , Prevention Against Acute Attacks , Pediatric Patients , About Takeda Pharmaceutical , Rare Genetics , Plasma Derived Therapies , Hospital Medicine , Inhibitor Subcutaneous , Medicines Agency , Last Accessed , Internal Medicine , Pediatric Patients Aged , With Hereditary Angioedema , Results From , Multicenter Phase , European Academy ,